Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases

References

• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–1619.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105(3):501–523.
   PubMed Web of Science ®Google Scholar
• Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol. 2013;7(4):341–351.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review. Dig Liver Dis. 2021;53(7):803–808.
   PubMedGoogle Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.
   PubMed Web of Science ®Google Scholar
• Lucas AT, Price LSL, Schorzman AN, et al. Factors affecting the pharmacology of antibody–drug conjugates. Antibodies. 2018;7(1):10.
   Google Scholar
• Chao Y-S, Visintini S. Biologics dose escalation for the treatment of inflammatory bowel disease: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018.
   Google Scholar
• Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLoS One. 2017;12(4):e0175099.
   PubMed Web of Science ®Google Scholar
• Naegeli A, Hunter T, Grabner M, et al. Identifying inadequate response among ulcerative colitis patients on an advanced therapy in a real-world administrative claims database. Inflamm Bowel Dis. 2021;27(Supplement_1):S20–S21.
   Web of Science ®Google Scholar
• Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS One. 2020;15(1):e0227914.
   PubMed Web of Science ®Google Scholar
• Helwig U, Mross M, Schubert S, et al. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. BMC Gastroenterol. 2020;20(1):211.
   PubMed Web of Science ®Google Scholar
• Mantzaris G, Bressler B, Kopylov U, et al. DOP55 a real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: results from EVOLVE. J Crohns Colitis. 2020;14(Supplement_1):S092–S094.
   Google Scholar
• Null KD, Xu Y, Pasquale MK, et al. Ulcerative colitis treatment patterns and cost of care. Value Health. 2017;20(6):752–761.
   PubMed Web of Science ®Google Scholar
• Comerford E, DiBonaventura M, Smith T, et al. P024 treatment patterns of biologic therapies used to treat ulcerative colitis: a retrospective database analysis in the United States. Am JGastroenterol. 2019;114:S7.
   PubMed Web of Science ®Google Scholar
• Smith TW, DiBonaventura M, Gruben D, et al. Dose escalation and treatment patterns of advanced therapies used to treat ulcerative colitis: a retrospective database analysis in the United States. Am J Gastroenterol. 2018;113(Supplement):S353.
   Google Scholar
• Shah NB, Haydek J, Slaughter J, et al. Risk factors for medication nonadherence to self-injectable biologic therapy in adult patients with inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(2):314–320.
   PubMed Web of Science ®Google Scholar
• Moran K, Null K, Huang Z, et al. Retrospective claims analysis indirectly comparing medication adherence and persistence between intravenous biologics and oral small-molecule therapies in inflammatory bowel diseases. Adv Ther. 2019;36(9):2260–2272.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Spencer EA, Colombel JF, et al. Approach to the management of recently diagnosed inflammatory bowel disease patients: a user’s guide for adult and pediatric gastroenterologists. Gastroenterology. 2021;161(1):47–65.
   PubMed Web of Science ®Google Scholar
• Chan W, Chen A, Tiao D, et al. Medication adherence in inflammatory bowel disease. Intest Res. 2017;15(4):434–445.
   Google Scholar
• Bewtra M, Fairchild AO, Gilroy E, et al. Inflammatory bowel disease patients’ willingness to accept medication risk to avoid future disease relapse. Am J Gastroenterol. 2015;110(12):1675–1681.
   Google Scholar
• Bewtra M, Reed SD, Johnson FR, et al. Variation among patients With Crohn’s disease in benefit vs risk preferences and remission time equivalents. Clin Gastroenterol Hepatol. 2020;18(2):406–414.e7.
   Google Scholar
• Gutiérrez A, Rodríguez-Lago I. How to optimize treatment with ustekinumab in inflammatory bowel disease: lessons learned from clinical trials and real-world data. Front Med. 2021;8:640813.
   Web of Science ®Google Scholar
• D'Amico F, Parigi TL, Fiorino G, et al. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019;12:1756284819848631.
   Web of Science ®Google Scholar
• Weisshof R, Aharoni Golan M, Sossenheimer PH, et al. Real-world experience with tofacitinib in IBD at a tertiary center. Dig Dis Sci. 2019;64(7):1945–1951.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, AGA Institute Clinical Guidelines Committee, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–1461.
   PubMed Web of Science ®Google Scholar